Abstract
Multiple myeloma (MM) is the second most common oncohematologic disease. Most patients are older than 65 years at diagnosis, and different therapeutic options are available depending on the age of the patient. For those younger than 65 years, autologous stem cell transplantation is the standard of care, whereas in older patients the better choice is conventional chemotherapy. The introduction of thalidomide, bortezomib, and lenalidomide, which target MM cells and the bone marrow microenvironment, has changed the therapeutic options in newly diagnosed patients with MM.
Similar content being viewed by others
References and Recommended Reading
Barlogie B, Kyle RA, Anderson KC, et al.: Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US intergroup trial S9321. J Clin Oncol 2006, 24:929–936.
Alexanian R, Barlogie B, Tucker S: VAD-based regimens as primary treatment of multiple myeloma. Am J Hematol 1990, 33:86–89.
Cavallo F, Boccadoro M, Palumbo A: Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther Clin Risk Manage 2007, 3:1–10.
Rajkumar SV, Blood E, Vesole D, et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24:431–436.
Rajkumar SV, Hussein M, Catalano J, et al.: A multicenter, randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as initial therapy for newly diagnosed multiple myeloma [abstract 795]. J Clin Oncol 2006, 24:426s.
Cavo M, Zamagni E, Tosi P, et al.: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005, 106:35–39.
Macro M, Divine M, Uzunhan Y, et al.: Dexamethasone + thalidomide (Dex/Thal) compared to VAD as pre-transplant treatment in newly diagnosed MM: a randomized trial [abstract]. Blood 2006, 108:57a.
Barlogie B, Tricot G, Anaissie E, et al.: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021–1030.
Goldschmidt H, Sonneveld P, Breitkreutz I, et al.: HOVON 50/GMMGHD3-trial: phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years [abstract]. Blood 2005, 106:128a.
Zangari M, Barlogie B, Anaissie E, et al.: Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126:715–721.
Rajkumar SV: Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proc 2005, 80:1549–1551.
Baz R, Li L, Kottke-Marchant K, et al.: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005, 80:1549–1551.
Naina HVK, Lacy MQ, Dispenzieri A, et al.: Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma [abstract]. Blood 2005, 106:970a.
Dimopoulos MA, Anagnostopoulos A, Terpos E, et al.: Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006, 91:252–254.
Abdelkefi A, Torjman L, Ben Romdhane N, et al.: First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005, 36:193–198.
Anderson K, Richardson P, Chanan-Khan AA, et al.: Single agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study [abstract]. J Clin Oncol 2006, 24:423s.
Jagannath S, Durie B, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma [abstract]. Blood 2005, 106:231a.
Harousseau J-L, Attal M, Leleu X, et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results from an IFM phase II study. Haematologica 2006, 91:1498–1505.
Harousseau J-L, Marit G, Caillot D, et al.: Velcade/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM). An interim analysis of the IFM 2005-01 randomized multicenter phase III trial [abstract]. Blood 2006, 108:21a.
Rosinol L, Oriol A, Mateos MV, et al.: Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007, 25:4452–4458.
Oakervee HE, Popat R, Curry N, et al.: PAD combination therapy (PS341/bortezomib doxorubicin and examethasone) for previously untreated multiple myeloma. Br J Haematol 2005, 129:755–762.
Popat R, Oakervee HE, Curry N, et al.: Reduced dose PAD combination therapy (PS341/bortezomib doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood 2005, 106:717a.
Wang M, Delasalle K, Giralt S, et al.: Rapid control of previously untreated multiple myeloma with bortezomibthalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood 2005, 106:231a.
Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113–3120.
San Miguel JF, Richardson P, Sonneveld P, et al.: Frequency, characteristics and reversibility of peripheral neuropathy (PN) in the APEX trial [abstract]. Blood 2005, 106:111a.
Lonial S, Richardson P, Sonneveld P, et al.: Haematologic profile in the phase III APEX trial [abstract]. Blood 2005, 106:97a.
Lacy M, Gertz M, Dispenzieri A, et al.: Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed multiple myeloma: response to therapy, time to progression and survival [abstract]. Blood 2006, 108:798a.
Rajkumar SV, Hajman SR, Lacy MQ, et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma. Blood 2005, 106:4050–4053.
Rajkumar V, Jacobus S, Callander N, et al.: Randomized phase III trial of lenalidomide plus high dose dexamethasone versus lenalidomide plus low dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2006, 108:799a.
Niesvizky R, Jayabalan DS, Christos PJ, et al.: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101–1109.
Ohara T, Morishita T, Suzuki H, et al.: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 2004, 24:3723–3730.
Niesvizky R, Bergsagel P, Pearse RN, et al.: Claritromycin potentiates the response of dexamethasone in chemotherapy naïve multiple myeloma patients: a prospective, sequential, randomized trial [abstract]. Blood 2002, 1100:389b.
Mileshkin L, Prince HM: The adverse prognostic impact of advance age in multiple myeloma. Leuk Lymphoma 2005, 46:951–966.
Alexanian R, Haut A, Khan AU, et al.: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969, 208:1680–1685.
Myeloma Trialists’ Cooperative Group: Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998, 16:3832–3842.
Facon T, Mary J, Pegourie B, et al.: Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006, 107:1292–1298.
Palumbo A, Bringhen S, Caravita T, et al.: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized control trial. Lancet 2006, 367:825–831.
Facon T, Mary JY, Hulin C, et al.: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209–1218.
Hulin C, Virion J, Leleu X, et al.: Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial [abstract]. J Clin Oncol 2007, 25(Suppl):8001.
Palumbo A, Bringhen S, Falco P, et al.: Time to first progression but not B2-microglobulin predicts outcome in myeloma patients who receive thalidomide as salvage therapy. Cancer 2007, 110:824–829.
Ludwig H, Drach J, Tothova E, et al.: Thalidomide-dexamethasone vs melphalan prednisolone as first line treatment in elderly patients with multiple myeloma: an interim analysis [abstract]. Blood 2005, 106:231a.
Almond JB, Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16:433–443.
Mateos MV, Hernandez JM, Hernandez MT, et al.: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006, 108:2165–2172.
Palumbo A, Falco P, Corradini P, et al.: Melphalan, prednisone and lenalidomide treamtent for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4458–4465.
Palumbo A, Bringhen S, Petrucci MT, et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104:3052–3057.
Palumbo A, Bringhen S, Bertola A, et al.: Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)). Leukemia 2004, 18:133–138.
Berenson JR, Crowley J, Grogan TM, et al.: Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma. Blood 2002, 99:3163–3168.
Attal M, Harousseau JL, Leyvraz S, et al.: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289–3294.
Spencer A, Prince M, Roberts AW, et al.: First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) [abstract]. Blood 2006, 108:58a.
Abdelkefi A, Ladeb S, Torjman L, et al.: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008, 111:1805–1810.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Palumbo, A., Magarotto, V., Larocca, A. et al. Treatment of newly diagnosed multiple myeloma. Curr Hematol Malig Rep 3, 107–114 (2008). https://doi.org/10.1007/s11899-008-0016-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11899-008-0016-8